Form 4: STAAR SURGICAL Co-CEO Foust Reports Equity Changes

STAAR SURGICAL's Interim Co-CEO and President & COO, Warren Foust, reported the acquisition of common stock through RSU vesting and a new RSU grant.

Summary

• Warren Foust, Interim Co-CEO and President & COO of STAAR SURGICAL CO (STAA), reported changes in his beneficial ownership of company securities.
• On March 12, 2026, Foust acquired 8,175 shares of common stock upon the vesting of Restricted Stock Units (RSUs) granted on March 12, 2024.
• On March 14, 2026, Foust acquired 19,550 shares of common stock from RSUs granted on March 14, 2025.
• Also on March 14, 2026, Foust acquired an additional 9,775 shares of common stock from another RSU grant on March 14, 2025.
• Following these transactions, Foust's direct beneficial ownership of common stock increased to 63,588 shares, which includes previously granted RSUs subject to future vesting.
• A new annual equity award of 45,117 Restricted Stock Units was granted to Foust on March 13, 2026, which will vest in three equal installments on March 13, 2027, March 13, 2028, and March 13, 2029.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a routine, slightly positive report reflecting ongoing executive compensation and retention, which is generally a good sign for stability and alignment of interests.

Positives

• The vesting of RSUs and the grant of new RSUs demonstrate ongoing equity compensation for a key executive, aligning management's interests with shareholder value.
• The new annual equity award of 45,117 RSUs indicates continued commitment to retaining and incentivizing Warren Foust in his leadership role.

Future Outlook

Warren Foust has future RSU vesting events scheduled. Specifically, 8,175 shares from a March 2024 grant will vest on March 12, 2027. From March 2025 grants, 19,550 shares and 9,775 shares will vest on March 14, 2027, and 19,551 shares and 9,776 shares will vest on March 14, 2028. A new RSU grant from March 2026 will vest in three equal installments of 15,039 shares on March 13, 2027, March 13, 2028, and March 13, 2029.

Industry Context

StockSavvy.ai notes that equity compensation, such as Restricted Stock Units (RSUs), is a prevalent practice across the medical device and broader technology sectors. This method is widely used to attract, retain, and incentivize key executives by aligning their financial interests directly with the long-term performance and shareholder value of the company. The routine nature of these filings underscores a standard approach to executive compensation within the industry.

Comparison to Industry Standards

• The use of Restricted Stock Units (RSUs) as a form of executive compensation is a standard practice, comparable to compensation structures seen in companies like Alcon (ALC), Bausch Health (BHC), and Johnson & Johnson (JNJ) in the medical device and healthcare sectors.
• The vesting schedule, typically over several years, is consistent with industry norms designed to promote long-term executive retention and performance alignment, similar to those observed in peer companies' proxy statements.

Stakeholder Impact

• Shareholders: The continued equity compensation for a key executive like Warren Foust helps align management's long-term interests with shareholder value, potentially fostering stable leadership and strategic execution.
• Employees: The report reflects standard executive compensation practices, which can indirectly influence overall company morale and compensation structures.

Next Steps

• Future vesting of 8,175 shares from the March 12, 2024 RSU grant on March 12, 2027.
• Future vesting of 19,550 shares and 9,775 shares from the March 14, 2025 RSU grants on March 14, 2027.
• Future vesting of 15,039 shares from the March 13, 2026 RSU grant on March 13, 2027.
• Future vesting of 15,039 shares from the March 13, 2026 RSU grant on March 13, 2028.
• Future vesting of 19,551 shares and 9,776 shares from the March 14, 2025 RSU grants on March 14, 2028.
• Future vesting of 15,039 shares from the March 13, 2026 RSU grant on March 13, 2029.

Key Dates

Recommendation

This Form 4 details routine equity compensation for a key executive, including RSU vestings and a new grant. It does not provide new information on company performance or strategic direction that would alter an investment thesis, thus a 'hold' recommendation is appropriate as it's a standard, non-eventful insider transaction report.

Keywords

STAAR SURGICAL, STAA, Warren Foust, Form 4, SEC filing, Restricted Stock Units, RSU vesting, equity compensation, insider transaction, beneficial ownership